Search

Author/Creator Ferrara, R.

1. Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. (April 2020)

Authors:
Passiglia, F.; Bertolaccini, L.; Del Re, M.; Facchinetti, F.; Ferrara, R.; Franchina, T.; Malapelle, U.; Menis, J.; Passaro, A.; Pilotto, S.; Ramella, S.; Rossi, G.; Trisolini, R.; Novello, S.
Journal:
Critical reviews in oncology/hematology
Issue:
Volume 148(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. (February 2020)

Authors:
Passiglia, F.; Pilotto, S.; Facchinetti, F.; Bertolaccini, L.; Del Re, M.; Ferrara, R.; Franchina, T.; Malapelle, U.; Menis, J.; Passaro, A.; Ramella, S.; Rossi, G.; Trisolini, R.; Novello, S.
Journal:
Critical reviews in oncology/hematology
Issue:
Volume 146(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. (21st November 2016)

Authors:
Caccese, M.; Ferrara, R.; Pilotto, S.; Carbognin, L.; Grizzi, G.; Caliò, A.; Brunelli, M.; Cuppone, F.; Petraglia, S.; Scarpa, A.; Tortora, G.; Bria, E.
Journal:
Expert opinion on pharmacotherapy
Issue:
Volume 17:Number 17(2016)
Page Start:
2253
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. FRI0478 SEROLOGICAL AUTOIMMUNITY IN PATIENTS WITH RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS: CORRELATION WITH SEVERITY AND TREATMENT. (13th June 2020)

Authors:
Campochiaro, C.; Tomelleri, A.; Ferrara, R.; Lazzari, C.; De Luca, G.; Signorelli, D.; Bulotta, A.; Gregorc, V.; Garassino, M.; Dagna, L.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
836
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions. (October 2022)

Authors:
Marinello, A.; Vasseur, D.; Conci, N.; Lindsay, C.; Metro, G.; Ferrara, R.; Eisert, A.; Citarella, F.; Fallet, V.; Audugier-Valette, C.; Cousin, S.; Tabbò, F.; Russo, A.; Calles Blanco, A.; Iranzo Gomez, P.; Tagliamento, M.; Mezquita, L.; Ponce, S.; Besse, B.; Aldea, M.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S26
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils. (December 2022)

Authors:
Ferrara, R.; Lo Russo, G.; Ciniselli, C.M.; Bassani, B.; Calareso, G.; Duroni, V.; Di Gregorio, S.; Proto, C.; Prelaj, A.; De Toma, A.; Occhipinti, M.; Brambilla, M.; Manglaviti, S.; Mazzeo, L.; Ganzinelli, M.; De Braud, F.G.M.; Garassino, M.C.; Colombo, M.P.; Verderio, P.; Sangaletti, S.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗